R 2666 R 2666 Pill - brown & yellow capsule/oblong, 19mm
Pill with imprint R 2666 R 2666 is Brown & Yellow, Capsule/Oblong and has been identified as Gabapentin 300 mg. It is supplied by Actavis Elizabeth LLC.
Gabapentin is used in the treatment of Postherpetic Neuralgia; Back Pain; Chronic Pain; Epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 300 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for R 2666 R 2666




Gabapentin
- Imprint
- R 2666 R 2666
- Strength
- 300 mg
- Color
- Brown & Yellow
- Size
- 19.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Gamma-aminobutyric acid analogs
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Actavis Elizabeth LLC
- Inactive Ingredients
-
ferrosoferric oxide,
corn starch,
D&C Yellow No. 10,
FD&C Blue No. 1,
FD&C Blue No. 2,
FD&C Red No. 40,
gelatin,
mannitol,
propylene glycol,
ferric oxide red,
silicon dioxide,
sodium lauryl sulfate,
magnesium silicate,
titanium dioxide,
ferric oxide yellow,
shellac
Note: Inactive ingredients may vary.
Labelers / Repackagers
NDC Code | Labeler / Repackager |
---|---|
14550-0512 (Discontinued) | Actavis Pharma, Inc. |
68084-0563 (Discontinued) | Amerisource Health Services |
45963-0556 | Actavis Pharma, Inc. |
68084-0762 (Discontinued) | Amerisource Health Services |
More about gabapentin
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2,484)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: gamma-aminobutyric acid analogs
- Breastfeeding
- En español
Patient resources
- Gabapentin drug information
- Gabapentin Capsules
- Gabapentin Oral Solution
- Gabapentin Tablets (PHN)
- Gabapentin Tablets 600 mg and 800 mg
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.